Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has published preclinical data in Cancer Cells demonstrating the potential of its fusion protein candidate, TNX-1700, to enhance immunotherapy in gastric cancer. The study, conducted in collaboration with Columbia University Medical School, showed that the murine version of TNX-1700 increased survival rates and reduced metastases in mouse models by depleting immunosuppressive neutrophils and inhibiting cancer-driven granulopoiesis.
The human counterpart, TNX-1700, is currently under development for gastric and colorectal cancers. Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, highlighted the significance of these findings for advancing TNX-1700 as a solution to checkpoint resistance in solid tumors. This development is crucial for patients with gastric cancer, a disease known for its poor prognosis and limited treatment options, especially for those resistant to current immunotherapies.
For more details on the study, visit https://ibn.fm/PPxKC.
